WhatsApp
backNews Article

3B BlackBio Dx's Coris BioConcept Acquires Bilex SRL to Own Manufacturing Facility, Generating €140,000 Annual Savings

Acquisition of 100% shares finalized on November 18, 2026, securing property in Belgium's Créalys® Science Park and consolidating operations

3B BlackBio Dx Limited's subsidiary, Coris BioConcept SRL, announced the acquisition of 100% shares of Bilex SRL, owner of its manufacturing plant and office building in Gembloux, Belgium, for €274,817. This transition from tenant to owner aims to eliminate intercompany rental payments and generate annual savings of €140,000 before depreciation, enhancing infrastructure control without additional regulatory approvals.

20 hours ago|3BBLACKBIO-0.38%
3B BlackBio Dx LimitedAcquisition / Amalgamation / Merger / Demerger

3B BlackBio Dx Limited

Acquisition / Amalgamation / Merger / Demerger

Coris BioConcept SRL, a subsidiary of 3B BlackBio Dx Limited, acquired 100% ownership of Bilex SRL, the entity that owns the land and building of Coris's manufacturing plant and office in Gembloux, Belgium, for €274,817. This acquisition, completed on November 18, 2026, transitions Coris from tenant to owner, eliminating rental payments and generating annual savings.

Bilex SRL owns the facility located at 11, Rue Guillaume Fouquet, Gembloux, Belgium, including a modern building with laboratories and offices on a 6,443 m² land parcel.

The building, constructed in 2023, includes energy-efficient features such as 256 solar panels and large rainwater collection tanks supporting environmental sustainability.

The acquisition involved payment of €274,817 for shares, €1.32 million to cover unsecured loans to shareholders, and continuation of €2.11 million in long-term building loans at 1.3% average interest payable over 12 years.

The transition to ownership is expected to immediately save €140,000 annually before depreciation by removing rental costs, leaving only interest expenses and depreciation on the balance sheet.

Bilex SRL will become a wholly owned subsidiary of Coris BioConcept, supporting its global diagnostic pipeline with secure infrastructure and investment stability.

Highlights

  • Acquisition date: November 18, 2026
  • Acquisition cost: €274,817 plus €1.32 million unsecured loan repayment and €2.11 million building loans
  • Annual savings estimated at €140,000 before depreciation
  • Facility located in Créalys® Science Park, Gembloux, Belgium
  • Bilex SRL becomes a wholly owned subsidiary of Coris BioConcept

Key Data Snapshot

Acquisition date18 November 2026
Acquisition cost for shares€274,817
Unsecured loans repaid to shareholders€1.32 Million
Long-term building loans continuing€2.11 Million at 1.3% interest
Annual savings from acquisition€140,000 before depreciation
Facility location11, Rue Guillaume Fouquet, 5032 Gembloux, Belgium
Facility land area6,443 m²
Facility building surface area2,000 m²

What happened

  • Coris BioConcept SRL acquired 100% shares of Bilex SRL, the owner of its Belgium manufacturing facility, becoming owner-occupier.
  • Acquisition was finalized on November 18, 2026, transitioning from tenant to owner and eliminating intercompany rental payments.
  • The transaction involved cash payment, loan repayment, and assumption of long-term building financing.

Key details

  • The purchased building is located in Créalys® Science Park, Gembloux, built in 2023 with advanced labs and offices.
  • Facility includes environmental features such as solar panels and rainwater collection tanks.
  • Annual net savings of €140,000 before depreciation expected due to elimination of rental payments.
  • The long-term building loan of €2.11 million continues with low-interest rate of 1.3% for 12 years.
  • Bilex SRL will operate as a wholly owned subsidiary of Coris BioConcept post acquisition.

Background and context

  • Bilex SRL was incorporated in 2014 and owns the land and building housing Coris BioConcept's operations in Belgium.
  • Coris BioConcept is a subsidiary of 3B BlackBio Dx Limited, specializing in rapid diagnostic kits for antimicrobial resistance.
  • The acquisition aligns with Coris BioConcept’s goal for long-term cost optimization and securing permanent infrastructure support.

More News on Acquisition / Amalgamation / Merger / Demerger

View all

Latest corporate announcements and market updates in Acquisition / Amalgamation / Merger / Demerger.

View all news
3B BlackBio Dx's Coris BioConcept Acquires Bilex SRL to | Stockk News